Lifecore Biomedical, Inc. - Common Stock LFCR 深 沪
等待开盘 09-11 09:30:00 美东时间
7.045
-0.215
-2.96%
华盛通- 最 高7.245
- 今 开7.18
- 成交量 7.24万股
- 最 低 7.045
- 昨 收 7.26
- 总市值 2.61亿
- 52周最高 8.85
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 4.33
- 委 比 36.11%
- 总股本 3702.53万
- 历史最高 15.96
- 量 比 0.41
- 振 幅 2.75%
- 历史最低 1.52
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference
Minneapolis-based Lifecore Biomedical announced its participation in the 24th Annual Contract Pharma Conference in New Brunswick, NJ on Sept. 18-19 as a Gold Sponsor. The company will showcase its expertise in injectable pharmaceutical development and manufacturing at the event, aiming to enhance brand visibility and attract high-value business. Lifecore, a leading CDMO with over 40 years of experience, will also host customer meetings to expand ...
09-04 20:05
Keybanc Initiates Coverage On Lifecore Biomedical with Sector Weight Rating
Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector Weight rating.
09-04 17:44
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical announced its participation in three upcoming investor conferences: Morgan Stanley Global Healthcare Conference (Sept 8-10, New York), Barrington Research Virtual Fall Conference (Sept 16), and Jefferies CDMO Summit (Sept 17, London). Management will engage in fireside chats and investor meetings. A webcast of the Morgan Stanley session will be available on their investor website. Lifecore is an integrated CDMO specializing in...
09-02 20:05
Lifecore Biomedical Sees FY2026 Sales $74.000M-$76.000M vs $127.802M Est
Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $74.000 million-$76.000 million vs $127.802 million analyst estimate.
08-08 04:39
Lifecore Biomedical Q4 EPS $(0.06) Beats $(0.10) Estimate, Sales $36.444M Beat $35.363M Estimate
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 36.84 percent. This is a 70 percent increase over losses of $(0.20) per share from
08-08 04:14
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025
Lifecore Biomedical will release fourth quarter and fiscal year 2025 financial results on August 7, 2025. A webcast discussing the results will be held at 4:30 p.m. Eastern Time that day, accessible via the company’s website. Additionally, an archived version will be available for 30 days post-event. Lifecore, a fully integrated CDMO, specializes in sterile injectable pharmaceutical products and premium hyaluronic acid, with over 40 years of expe...
07-31 20:05
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical granted RSU and stock options to three new employees under its Equity Inducement Plan. The awards, totaling 6,338 RSUs and 29,575 stock options, were approved on July 11, 2025, as inducements to join the company. RSUs will vest after three years, while stock options, with a seven-year term, vest monthly beginning one year after the grant date.
07-17 20:05
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
Lifecore Biomedical has signed a 10-year commercial manufacturing and supply agreement with a key customer to further develop and commercialize a novel ophthalmic therapeutic. The agreement includes a multi-million-dollar statement of work for fill and finish services, with Lifecore manufacturing multiple batches, including PPQ batches. This long-term partnership aims to advance the therapeutic through clinical development and regulatory approval...
06-17 11:00
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
Lifecore Biomedical has received the remaining $10 million from the sale of its excess high-speed isolator filler, brought forward from the original 18-month plan. This, combined with the prior $7 million received, strengthens the company's balance sheet and underscores its disciplined capital management. Lifecore is using the funds to support growth initiatives, including the recent installation of a high-speed 5-head filler capable of generatin...
06-12 11:00
